Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

NCT04207255 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Opaganib
DRUG: Abiraterone
DRUG: Enzalutamide
DRUG: Opaganib

Sponsor

Medical University of South Carolina

Collaborators

[object Object]